SCHEMBL1129209

SCHEMBL1129209

CC(C)(c1ccccc1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.62
LPL P06858 12/20 0.62
P4HB P07237 1/20 0.46
ALDH1A1 P00352 1/20 0.46
ESR1 P03372 1/20 0.46
CYP3A4 P08684 1/20 0.46
ESR2 Q92731 1/20 0.46
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
F11 P03951 2/20 0.41
F2 P00734 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15165484 0.93 LPL (0.55) LIPGLPLP4HBESR2CA1
SCHEMBL24028674 0.87 LIPG (0.65) LIPGLPLP4HBESR2CA1
SCHEMBL19305515 0.87 LIPG (0.65) LIPGLPLP4HBESR2CA1
SCHEMBL25981605 0.86 LIPG (0.59) LIPGLPLP4HBCA1CA2
SCHEMBL25981372 0.86 LIPG (0.59) LIPGLPLP4HBCA1CA2
SCHEMBL1129175 0.86 LIPG (0.59) LIPGLPLP4HBCYP3A4CA1
SCHEMBL17725444 0.86 LPL (0.49) LIPGLPLP4HBESR2CA1
SCHEMBL19305547 0.85 LIPG (0.62) LIPGLPLP4HBCA1CA2
SCHEMBL12162902 0.85 LIPG (0.47) LIPGLPLP4HBALDH1A1ESR1
SCHEMBL12162899 0.84 LPL (0.47) LIPGLPLP4HBESR2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12201015-B2 Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device, and illumination device MITSUBISHI CHEMICAL CORPORATION (JP) 2025-01-14 US disclosed
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-11-16 US disclosed
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-11-16 US disclosed
US-20230257383-A1 COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-08-17 US disclosed
US-20230257383-A1 COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) 2023-08-17 US disclosed
EP-4186906-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) 2023-05-31 EP disclosed
EP-3971196-A1 IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND LIGHTING DEVICE Mitsubishi Chemical Corporation (JP) 2022-03-23 EP disclosed
US-20220069238-A1 IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-03 US disclosed
CN-113853381-A Iridium complex compound, composition containing iridium complex compound and solvent, organic electroluminescent element containing iridium complex compound, display device, and lighting device 三菱化学株式会社 2021-12-28 CN disclosed
WO-2020230811-A1 IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND LIGHTING DEVICE 三菱ケミカル株式会社 2020-11-19 WO disclosed
US-20160043325-A1 COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY AND LIGHTING MITSUBISHI CHEMICAL CORPORATION (JP) 2016-02-11 US disclosed
US-20160043325-A1 COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY AND LIGHTING MITSUBISHI CHEMICAL CORPORATION (JP) 2016-02-11 US disclosed
EP-2803671-A1 IRIDIUM COMPLEX COMPOUND, SOLUTION COMPOSITION CONTAINING IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE Mitsubishi Chemical Corporation (JP) 2014-11-19 EP disclosed
US-20140319505-A1 IRIDIUM COMPLEX COMPOUND, SOLUTION COMPOSITION CONTAINING THE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY, AND LIGHTING MITSUBISHI CHEMICAL CORPORATION (JP) 2014-10-30 US disclosed
US-20140319505-A1 IRIDIUM COMPLEX COMPOUND, SOLUTION COMPOSITION CONTAINING THE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY, AND LIGHTING MITSUBISHI CHEMICAL CORPORATION (JP) 2014-10-30 US disclosed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12201015-B2 Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device, and illumination device INF2, EMC2, INTS9 LIPG 4251/4885LPL 4208/4885P4HB 1304/4885
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 LIPG 4744/4885LPL 4530/4885P4HB 882/4885
US-20220069238-A1 IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE INF2, EMC2, INTS9 LIPG 4251/4885LPL 4208/4885P4HB 1304/4885
US-20230257383-A1 COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF BTK, WEE1, WEE2 LIPG 3280/4885LPL 3691/4885P4HB 2964/4885
US-20230364079-A1 COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF BTK, WEE2, WEE1 LIPG 1966/4885LPL 3112/4885P4HB 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.